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Neutralizing monoclonal antibodies against three major toxic components of Bothrops
atrox venom were produced and tested. The mAbs against phospholipase A2, hemorrhagic
metalloprotease, and thrombin-like enzymes were produced in large amounts and puriﬁed
with caprylic acid followed by ammonium sulfate precipitation. Puriﬁed mAbs were
analyzed by SDS-PAGE and their ability to neutralize the respective toxins was tested. Five
Swiss mice were injected i.p. with 13.5 mg of pooled mAbs and challenged via s.c. route
with venom. Survival rate was recorded for the next 48 h. All mice treated and challenged
with venom survived, whereas only one mouse in the control group survived. Bleeding
time in mice treated with mAbs was similar to that observed in control mice. Our results
show that monoclonal antibodies neutralized the lethal toxicity of Bothrops venom and
indicate that there is a reasonable possibility of developing antivenoms based on hu-
manized mAbs to treat victims of venomous animals in the future.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Antivenom immunotherapy still is the most effective
treatment for victims of venomous animals, particularly
snakes and scorpions. The efﬁcacy of conventional anti-
venoms in neutralizing most of the toxic properties of the
venom, including their lethality, has been improved by the
introduction of modiﬁcations in production protocols
dictated by new discoveries in basic immunology and
protein chemistry. Moreover, immunization schedules are; fax: þ55 22 2739
ashiro@yahoo.com.br
basic immunological
. All rights reserved.continuously adapted, new adjuvants have been intro-
duced, and the resulting antibodies are better isolated,
assayed, and characterized. Despite the progress in the
preparation of conventional antivenoms, the risk of adverse
reactions remains (Cardoso et al., 1993; Otero-Patiño et al.,
1998; FUNASA, 2001). Although F(ab0)2 rich antivenoms are
just as effective as the rich intact IgG in neutralizing venom
toxins, their side-effects and ability to activate the host
complement system have not yet been eliminated
(Chippaux and Goyffon, 1991; Chippaux, 1991).
In Brazil, of the 17,704 snake accidents (incidence rate:
10.4 accidents/100,000 inhabitants) reported in 1999, 21%
(3697) snake bites occurred in the northern region, where
only 7.6% of the Brazilian population live (28.6 accidents/
100,000 inhabitants) (IBGE, 2004). In that region, Bothrops
atrox is the major snake group responsible for accidents
(FUNASA, 2001).
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Bothrops species, is a complex mixture that includes pro-
teins exhibiting proteolytic activity (Rosenfeld, 1971;
Kamiguti and Cardoso, 1989). Some of these proteins are
proteases, whose substrates include components of the
blood clotting system such as factors XII, X, and ﬁbrinogen
(Nahas et al., 1964; Kamiguti et al., 1992). Other proteins in
the venom are zinc-dependent metalloproteinases (SVMP),
most of which have hemorrhagic-inducing properties
(Ohsaka, 1979; Bjarnason and Fox, 1988), and phospholi-
pase A2 (PLA2), which have been shown to be involved in
myonecrosis and inﬂammation (Maragananore et al., 1984;
Gutierrez and Ownby, 2003).
Conventional antivenoms are prepared by immunizing
horses with venom from a single snake species or amixture
of venoms from different species. The aim of immunization
is to elicit high levels of antibodies that bind to and
neutralize most relevant toxins. Conversely, immunization
also elicits undesirable antibodies directed to non-toxic
venom components and irrelevant venom epitopes, ac-
cording to Harrison et al. (2011) 95% of IgGs comprising
current antivenoms are not therapeutic. All the irrelevant
proteins contribute to some antivenom therapy side effects.
For instance, even though immunoglobulin G(T) is effective
in the treatment of envenomed patients, a high incidence
(37–87%) of early anaphylatic reactions requiring urgent
treatment with adrenalin and antihistamines have been
observed (Cardoso et al., 1993). Mixtures containing mono-
speciﬁc antibodies against a repertoire of epitopes in toxic
venoms could help achieve two desirable immunotherapy
requirements: the use of smaller amounts of antivenom,
and higher speciﬁcity. In addition, the development of
bothropic antivenoms should consider the need to reduce
components other than the desired venom-speciﬁc IgG or
their F(ab0)2 fragments and the use of a mixture of anti-
bodies restricted to the relevant toxic venom components.
The aim of our work was to develop in mice monoclonal
antibodies against some B. atrox venom components. Their
neutralizing properties were analyzed using some well
known pathological process induced by venom compo-
nents as indicators. Three speciﬁc neutralizing mAbs
(thrombin-like 6AD2-G5 clone, PLA2 A85/9-4 clone, and
Zn-metalloprotease 59/2-E4 clone) were prepared and
tested by their ability to neutralize the main B. atrox venom
toxins. These monoclonal antibodies will be used in the
future as raw reagents to prepare hybrid antibodies
expressing the mouse LV and HV regions molecular linked
into human LC and HC regions.
2. Material and methods
2.1. Venom and antivenom
B. atrox venom was kindly provided by the Laboratório
de Hepertologia, Instituto Butantan, São Paulo, SP, Brazil, in
the lyophilized form. The venom used in this work is a pool
of snake venom from Tucuruí, Pará, Brazil. Venom was
weighed, diluted in distilled water to a ﬁnal concentration
of 10 mg/ml, and stored at 20 C. Bothropic antivenom
(batch 0512219/B, expiry date April 2009) was provided by
Instituto Butantan.2.2. Animals
Swiss mice weighing between 18 and 22 g were used
throughout this study. Male and female adult BALB/c mice
were also used. Animals were bred at the Vivarium of
Isogenic Mice at the Center for Biosciences and Biotech-
nology of Universidade Estadual do Norte Fluminense
Darcy Ribeiro (UENF). All animals were housed in
controlled rooms and received water and food ad libitum
until used. When necessary, 250 mg of ketamine chloridrate
were used to anesthetize mice. This study was approved by
the Experimental Animals Committee of UENF.
2.3. Monoclonal antibody production
2.3.1. Hybridoma and ascitic ﬂuid
Hybridoma cells producing neutralizing mAbs against
serineproteinase (thrombin-like) clone 6AD2-G5 (Petretski
et al., 2000), PLA2 clone A85/9-4 (Kanashiro et al., 2002),
and hemorrhagin (Zn-metalloproteinase) clone 59/2-E4
(Barros et al., 1998) of B. atrox snake venom were cultured
with DMEN-F12 medium, supplemented with 10% FCS and
10 mg/mL gentamicin. Each culture was expanded and
1  106 cells were inoculated i.p. in adult BALB/c mice
previously i.p. injected with 400 ml mineral oil. After ten
days, mice were euthanized by CO2 inhalation, and the
ascitic ﬂuid was collected by abdominal puncture.
2.3.2. Monoclonal antibody puriﬁcation
Monoclonal antibodies were puriﬁed with caprylic acid
followed by ammonium sulfate precipitation (Steinbuch
et al., 1970). Brieﬂy, ascitic ﬂuid was diluted 1:3 in 60 mM
sodium acetate buffer, pH 4.0, and 0.4 mL caprylic acid was
added under agitation for 30 min at room temperature for
each 10 mL of ascitic ﬂuid. The mixture was centrifuged at
5000 g for 1 h and the supernatant was collected. After
centrifugation, the pH of supernatant was adjusted to 7.0
and ammonium sulfate was added under agitation to ach-
ieve a 45% concentration (w/v), and the mixture allowed to
stand at 4 C overnight. Precipitates were recovered by
centrifugation at 5000 g for 30 min, redissolved and
dialyzed against saline 0.9%, and immunochemically
analyzed by SDS-PAGE and Western blot.
2.3.3. Immunochemical analysis
Samples of dialyzed mAbs were subjected to 12% poly-
acrylamide gel electrophoresis (SDS-PAGE), according to
the method described by Laemmli (1970) with modiﬁca-
tions. The samples were dissolved in sample buffer (0.5 M
Tris–HCl buffer, pH 6.8 plus 10% SDS, 10% 2-b-mercaptoe-
thanol, and 0.5% bromophenol blue dye), boiled at 100 C,
loaded on 12% polyacrylamide gel, and run at 150 v. Protein
bands were stained with Coomassie brilliant blue and
subjected to computerized densitometric analysis (Bozzo
and Retamal, 1991). Western blot was performed, accord-
ing to a previously described method (Towbin et al., 1979).
2.3.4. Monoclonal antibody titration by ELISA
Binding ability of the puriﬁed mAbs to the respective
antigen was evaluated by ELISA test, according to the
methodology described by Almeida et al. (1998). Brieﬂy, B.
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like toxin (10 mg/mL) was diluted in 0.1 M carbonate/bi-
carbonate buffer (pH 9.6) and adsorbed to the ELISA plate.
After a blocking step with gelatin, mAbs were diluted and
added to wells. ELISA plates were incubated at 37 C for
45min followed by the addition of secondary antibody. The
reaction was developed with o-phenylenediamine plus
hydrogen peroxide, and color development was stopped
with 50 mL 3 N H2SO4. Plates were read spectrophotomet-
rically at 490 nm.
2.4. Neutralizing properties of mAbs
2.4.1. Neutralization of myonecrosis
Fortymicrograms ofmyotoxic PLA2 from B. atrox venom,
puriﬁed according to the method described by Kanashiro
et al. (2002), were preincubated with 140 mg A85/9-
4 mAb, and then aliquots of the mixtures were injected into
the gastrocnemius muscle of ﬁve Swiss mice. Similarly,
samples of myotoxic PLA2 were preincubated with non-
related mouse IgG, instead of mAbs, and injected into ﬁve
control mice. Blood samples were collected 1 h later and
serum creatine kinase (CK) activity was measured using
Merck Granutest 2.5.
2.4.2. Neutralization of hemorrhagic activity
Concentrations of 0, 25, 50, and 100 mg of puriﬁed 59/2-
E4 mAb were incubated with 5 mg of B. atrox venom and
injected i.d. into the shaved back of three Swiss mice. After
30min, animals were euthanized and the size and intensity
of subcutaneous hemorrhage in injected areas was
estimated.
2.4.3. Neutralization of bleeding
3.5 mg samples of puriﬁed mAb 6AD2-G5 were pre-
incubated with 150 mg of venom for 30 min at ambient
temperature and i.p. injected into ﬁve Swissmice (18–22 g).
One hour after inoculation, the tips of tails were cut and
immersed in 10mL of distilledwater until bleeding stopped
(Assaﬁmet al. 2006; Greene et al. 2010). The optical density
of samples was determined in a spectrophotometer at
410 nm. In addition, 500 mL of horse F(ab0)2 bothropic an-
tivenom was used as positive control group, whereas
venom plus saline was injected into the mice as negative
control.
2.4.4. Neutralization of lethality
Groups of ﬁve Swiss mice (18–20 g) were injected i.p.
with 500 mL saline containing 5 mg 59/2-E4, 5 mg A85/9-4,
and 3.5 mg 6AD2-G5 mAb. After 30 min, mice were chal-
lenged s.c. with 350 mg of crude venom. Controls were
injected i.p. with 500 mL saline and challenged s.c. with
350 mg of venom. In another experiment 10.5 mg of mAbs
(3.5 mg of each mAbs) were incubated with 200 mg of
venom for 30 min at 37 C followed i.p. injection into the
mice. The control group received 200 mg of venom. Sur-
vival/death rates were recorded at 24 and 48 h.
2.4.5. Histological examination
A mixture containing 3.45 mg each of mAb 59/2-E4,
A85/9-4, and 6AD2-G5 incubated with 200 mg of venomwas injected i.p. in groups of six Swiss mice. Controls
received only saline and venom. After 2, 24, and 48 h, two
mice from each group were euthanized by CO2 inhalation
and their tissues and organs removed and ﬁxed in 10%
neutral p-formaldehyde. Tissues were dehydrated in
ascending concentrations of ethanol (70–100%) and
embedded in parafﬁn using an automatic tissue processor
(TP 1020, Leica, Germany). Then, 5 mm sections were
stained with hematoxylin-eosin and tissue sections were
observed using a digital image analysis system coupled to a
microscope (Zeiss axioplan/axiocam, Germany).
3. Results and discussion
We evaluated the lethality neutralization by mono-
clonal antibodies against three major toxic components of
B. atrox venom to test the prospects of developing
bothropic antivenom based on monoclonal antibodies.
General features of puriﬁed mAb speciﬁc to ser-
ineproteinase (thrombin-like 6AD2-G5 clone), PLA2 (A85/
9-4 clone), and hemorrhagin (Zn-metalloproteinase 59/2-
E4 clone) are shown in Fig. 1. When submitted to SDS-
PAGE analysis, all three mAb preparations demonstrated
two major protein bands, one of around 55 kDa and one of
approximately 29 kDa, suggestive of immunoglobulin
heavy and light chains, in addition to several minor
contaminant bands (Fig. 1A). Western blot analyses, using
anti-mouse IgG as the primary antibody, conﬁrmed that the
two major protein bands correspond to the mouse IgG
heavy and light chains (Fig. 1B). In addition, densitometric
analysis of the SDS-PAGE was performed to estimate the
purity of the mAb preparations. The purity grade for mAbs
A85/9-4 (46%), 59/2-E4 (45%), and 6AD2-G5 (37%) is shown
in Fig. 1C.
The ability of puriﬁed mAbs to recognize the respective
toxins by ELISA is shown in Fig. 2. The mAbs A85/9-4 and
59/2-E4, which recognize phospholipase A2 and Zn-
metalloproteinase, respectively, were able to bind the an-
tigen at the lowest concentration tested (10 ng/mL) at a
relatively high optical density when compared to the con-
trol sample (Fig. 2A, B). However, mAb 6AD2-G5 was not as
effective as the other two, as the ﬁnal dilution that recog-
nized the antigenwas 8 mg/mL (Fig. 2C). In a previous study
from our group, Petretski et al. (2000) showed that mAb
6AD2-G5 was very effective in neutralizing the catalytic
activity of the thrombin-like enzyme and also it recognized
a conformational epitope of the toxin. In fact, this could
explainwhymAb 6AD2-G5weakly binds the target antigen
adsorbed to the solid phase of the ELISA plate, as the
adsorption of the antigen to the plastic surface could result
in slight changes in the antigen epitope structure.
The neutralizing properties of the mAbs against their
respective toxins are shown in Fig. 3. The ability of three
different mAb 59/2-E4 concentrations to neutralize hem-
orrhage induced by 5 mg of venom is shown in Fig. 3A.
Hemorrhage neutralization by the mAb 59/2-E4 was seen
in a dose-dependent manner from 25 mg to 100 mg of
antibody tested. Conversely, the ability of mAb 59/2-E4 to
neutralize the enzyme’s catalytic activity was negligible
(data not shown) when azocasein was used as substrate.
This result indicates that mAb 59/2-E4 does not bind to the
Fig. 1. SDS-PAGE and Western blot analysis of puriﬁed mAbs. A – SDS-PAGE analysis of the mAbs puriﬁed with caprylic acid and ammonium sulfate precipitation.
Lane 1: puriﬁed A85/9-4 mAb (15 mg); lane 2: puriﬁed 59/2-E4 mAb (15 mg); lane 3: puriﬁed 6AD2-G5 mAb (15 mg). Left lane: molecular weight marker. B – mAb
heavy and light chain identiﬁcation by Western blot analysis. SDS-PAGE, run according to Figure 1A, was transferred to nitrocellulose membrane and incubated
with anti-mouse IgG conjugated to peroxidase. Lane 1: A85/9-4 mAb (15 mg); lane 2: 59/2-E4 mAb (15 mg); lane 3: 6AD2-G5 mAb (15 mg). C – Densitometry
analysis of the SDS-PAGE.
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patternwas observed for mAbMAJar 3 against jararhagin, a
Bothrops jararaca PIII metalloproteinase (Tanjoni et al.,
2003). MAJar 3 efﬁciently neutralized the hemorrhagic
activity of jararhagin without blocking the catalytic activity
of the enzyme and was shown to bind to the C-terminal
portion of the disintegrin domain, which could be in
conformational proximity to the catalytic domain or func-
tionally modulate the hemorrhagic activity of the snake
venom metalloproteinase. Because mAb 59/2-E4 neutral-
ized the biological activity of hemorrhagin, which has
properties similar to those of MAJar 3, it is possible that
both mAbs recognize the same epitope.
The myotoxic activity induced by PLA2 was inhibited
when the enzyme was incubated with mAb A85/9-4 fol-
lowed by injection into the gastrocnemius muscle of mice
(Fig. 3B). The CK serum level was drastically reduced in
mice treated with the speciﬁc mAb when compared to
control mice, treated with the non-speciﬁc IgG. Moreover,
mAb A85/9-4 was not able to neutralize the catalytic ac-
tivity of the enzyme (data not shown). In fact, a lack of
correlation between the enzymatic activity of snake venom
PLA2 and myotoxic activity has been shown in several
studies (Kini and Evans, 1989; Diaz-Oreiro and Gutiérrez,
1997; Kanashiro et al., 2002).
The effective neutralization of mAb 6AD2-G5 was pre-
viously assessed in vivo in a murine tail bleeding model(Greene et al., 2010). Fig. 3C summarizes bleeding time of a
group of mice injected i.p. with a mixture of mAb 6AD2-G5
or antivenom with B. atrox venom. Mouse-tail bleeding
time indicated no signiﬁcant differences in blood loss be-
tween mice treated with mAb and antivenom. Petretski
et al. (2000) showed that mAb 6AD2-G5 was also very
effective in neutralizing ﬁbrinogen-clotting and catalytic
activities of the thrombin-like enzyme of B. atrox venom. In
addition, it also neutralized the thrombin-like enzyme
from other Bothrops species. These results indicate that the
neutralizing properties of mAb 6AD2-G5 could be used for
new therapeutic approaches in bothropic accidents. Inter-
estingly, we easily succeeded in neutralizing the catalytic
activity of the thrombin-like enzyme in the venom using
mAb 6AD2-G5. We then immunized rabbit, chicken, rat,
and guinea pig to obtain sera to neutralize the catalytic
activity of PLA2 and Zn-metalloproteinase from B. atrox
venom. The resulting sera recognized the enzymes, but
could not block their catalytic activity (data not shown).
Lethality assay performed in mice pretreated with mAb
mixture showed 100% survival and venom control group of
mice experienced an 80% death rate. When mAbs mixture
plus venom were incubated before injection into the mice
80% of animals survived and the control group of venom
100% of death was observed (Table 1), showing that mAbs
assayed by both methods neutralize lethality of venom.
Although the protein concentrations in those experiments
Fig. 2. Titration of monoclonal antibodies by ELISA. Nunc maxisorp ELISA
plate was activated with 10 mg/mL of antigens and incubated with several
dilutions of monoclonal antibodies. A – mAb A85/9-4; B – mAb 59/2-E4; C –
mAb 6AD2-G5.
Fig. 3. Neutralization of the toxic components of Bothrops atrox venom by
monoclonal antibodies. A – Neutralization of hemorrhagic activity. Con-
centrations of 59/2-E4 mAb (2) 25 mg, (3) 50 mg, and (4) 100 mg, (1) venom
positive control, were incubated with 5 mg of the venom followed by i.d.
injection into the mice. Hemorrhagic area was evaluated 30 min later. B –
Inhibition of myotoxic activity by mAb A85/9-4. 140 mg of mAb were incu-
bated with 40 mg of puriﬁed PLA2, followed by IM injection into the mouse
gastrocnemius muscle. Myotoxicity was evaluated by serum CK level. C –
Bleeding time induced by the venom.
Table 1
Mice protection assay.
Groups mAbs/route Venom/route Survived/total
aAntibody c13.5 mg/i.p. 350 mg/s.c. 5/5
aVenom Saline/i.p. 350 mg/s.c. 1/5
bAntibody d10.5 mg/i.p. 200 mg/i.p. 4/5
bVenom Saline/i.p. 200 mg/i.p. 0/5
a mAbs and saline was injected i.p. and 30min later venomwas injected
via s.c.
b Pool of mAbs and venom or saline and venom were incubated for
30 min and injected i.p.
c mAbsmixture: 5 mg of mAbs A85/9-4 and 59/2-E4, and 3.5 mg of mAb
6AD2-G5.
d mAbs mixture: 3.5 mg of each mAbs A85/9-4, 59/2-E4 and 6AD2-G5.
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contaminants (55–63% impurity). Therefore, from the total
protein administered to the animals, less than 40% could be
considered speciﬁc antibodies. A similar experiment per-
formed by da Silva et al. (2007) using polyvalent antivenom
also showed lower antivenom efﬁciency when antivenom
was injected into the animal prior to local challenging with
venom, when compared to antivenom and venom pre-
incubation followed by local injection into the mouse. We
believe that antivenom administration by i.p. or i.v. route
and venom challenge performed subcutaneously are more
similar to the natural mechanism of ophydic accidents.
Mouse tissues used in lethality neutralization assays
underwent histopathological analysis. Two hours after
inoculation, the animals presented bristled hair, dyspnea,
and exhaustion, in contrast to animals treatedwith themAb
pool, whose clinical signs were less evident. During nec-
ropsy, euthanized animals exhibited severe blood collection
in the peritoneal cavity (hemoperitoneum). This observationwasmuchmore evident in the positive control group than in
the group treated with the mAbs. Histopathology of perito-
neal wall sections (serous membrane and skeletal muscle of
the ﬂoor of the dorsal cavity) in mAb-treated animals (2 h)
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intravascular leukocytes (leukocytosis), edema, and discreet
hemorrhage (Fig. 4A). Cavity samples from control animals
were represented by accentuated endomisial edema with
muscular ﬁber dissociation and moderate hemorrhage
(Fig. 4B). In addition, some muscle ﬁbers exhibited coagu-
lation necrosis (hyalinized: without striations and slightly
eosinophilic). The pancreas from mice treated with mAbs
exhibited hemorrhage and discreet edema in the intestine/Fig. 4. Histopathological analysis of mice inoculated i.p. with a mixture of mAbs and
treated with mAb mixture; B and D: mice injected with venom; F: normal mice. Arr
muscle ﬁber hyalinization. Magniﬁcation A, F – 200; B, D, E – 400; C – 100.pancreas interface (Fig. 4C). Conversely, controls that
received only B. atrox venom showed evidence of extensive
solid hemorrhage and acinar cell dissociation in pancreatic
samples using conventional microscopy (Fig. 4D). Although
Camargoet al. (2005)observedacutepancreatitis inducedby
phospholipase A2 from Bothrops venom in rats, the changes
in the peritoneal cavity and pancreas found in our study are
probably associated to the direct contact between the mAb
and venom mixture injected into the peritoneal cavity.venom. A, B: peritoneumwall; C, D: pancreas; E, F: kidney. A, C, and E: mice
ow – intravascular leukocytosis; star – edema and hemorrhage; arrowhead –
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Fig. 5. Neutralization of the hemorrhage induced by Bothrops atrox venom.
Anesthetized mice were inoculated i.p. with the previously incubated
mixture of venom and mAb pool. Bleeding time was determined 30 min
later.
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was not signiﬁcantly different from that of control animals
(Fig. 4E, F). Although human deaths by Bothrops envenom-
ation are generally associated to acute renal failure (Milani Jr.
et al., 1997), renal failure was not well reproduced inmurine
models. Moreover, several studies that evaluated renal al-
terations caused by bothropic venom in ratswere performed
using i.v. injectionorex-vivo renal perfusion (Gutiérrez et al.,
2009; Boer-Lima et al., 1999), and this could explain the lack
of alterations in kidney samples evaluated in this study.
Mice inoculated with the mAb and venom mixture lost
the same quantity of blood as negative controls when
bleeding time was determined (Fig. 5). In contrast, high
blood loss was observed in mice given venom only. To our
knowledge this is the ﬁrst study to show that neutralizing
monoclonal antibodies against threemajor Bothrops venom
toxins abrogates the venom activity.
Our results show that a pool of three mAbs neutralizes
the lethal activity of B. atrox venom. Nevertheless, we
believe that the action of toxins present in minor concen-
tration in the venom (Neiva et al., 2009), which could act
alone or synergistically with other toxins, must also be
considered. Moreover, intraspeciﬁc (Núñez et al., 2009) and
interspeciﬁc (Queiroz et al., 2008) variation in venom
characteristics should also be investigated when devel-
oping antivenoms based on monoclonal antibodies.
Monoclonal antibodies similarly to polyclonal anti-
bodies when injected into xenogeneic animals induce
antibody production against either their constant and
variable regions resulting in a short circulating life. Owing
to these restrictions monoclonal antibodies were devel-
oped to serve as raw materials for design different smaller
antivenom antibody formats Fab and scFv (Holliger and
Hudson, 2005). The aims of our work were therefore to
obtain monoclonal antibodies directed to biologically sig-
niﬁcant toxin epitopes expressed on B. atrox lethal toxins.
The corresponding hybridomas will be used to develop
humanized or antibody fragments as nonimmunogenic
in vivo biopharmaceutical endowed with superior bio-
distribution and blood clearance properties.
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